SCHEMBL29173496

SCHEMBL29173496

CNc1nc(Nc2cccc(N3CCN(C)CC3)c2)c(C(=O)OC)nc1-c1cncc2c1ncn2C

nearest known ligand 0.42

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ EML4 Q9HC35 1/20 0.42
▸ ALK Q9UM73 1/20 0.42
▸ EGFR P00533 5/20 0.41
▸ CDK2 P24941 7/20 0.40
▸ AURKA O14965 2/20 0.40
▸ CCNA2 P20248 5/20 0.39
▸ JAK2 O60674 4/20 0.39
▸ JAK3 P52333 3/20 0.39
▸ CCNA1 P78396 2/20 0.39
▸ JAK1 P23458 1/20 0.39
▸ PTK2 Q05397 2/20 0.39
▸ CCNT1 O60563 3/20 0.38
▸ CDK9 P50750 3/20 0.38
▸ BRD4 O60885 3/20 0.37
▸ CDK1 P06493 1/20 0.37
▸ CCNB1 P14635 1/20 0.37
▸ CDK7 P50613 1/20 0.37
▸ CCNH P51946 1/20 0.37
▸ BTK Q06187 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30205989 0.93 CDK2 (0.40) EML4ALKEGFRCDK2CCNA2
SCHEMBL29173447 0.93 CDK2 (0.40) EML4ALKEGFRCDK2CCNA2
SCHEMBL24944460 0.92 EML4 (0.51) EML4ALKEGFRCDK2AURKA
SCHEMBL30205535 0.92 EML4 (0.51) EML4ALKEGFRCDK2AURKA
SCHEMBL29173546 0.91 JAK2 (0.42) ALKEGFRCDK2CCNA2JAK2
SCHEMBL30206211 0.91 JAK2 (0.42) ALKEGFRCDK2CCNA2JAK2
SCHEMBL29173442 0.87 EGFR (0.40) EML4ALKEGFRJAK2JAK3
SCHEMBL30206107 0.85 CYP1A2 (0.35) CDK2AURKACCNA2CCNA1BTK
SCHEMBL29173378 0.85 CYP1A2 (0.35) CDK2AURKACCNA2CCNA1BTK
SCHEMBL29173551 0.85 EGFR (0.37) EML4ALKEGFRCDK2BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4373817-B1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2025-05-21 — — EP disclosed
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2024-11-14 — — US disclosed
EP-4373817-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER Astrazeneca AB (SE) 2024-05-29 — — EP disclosed
CN-117693503-A Substituted pyrazine-2-carboxamides as HPK1 inhibitors for the treatment of cancer 阿斯利康(瑞典)有限公司 2024-03-12 — — CN disclosed
WO-2023001794-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER ASTRAZENECA AB (SE) 2023-01-26 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240374606-A1 SUBSTITUTED PYRAZINE-2-CARBOXAMIDES AS HPK1 INHIBITORS FOR THE TREATMENT OF CANCER PDXK, PGK1, PGK2 EML4 2189/4885ALK 2002/4885EGFR 2072/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback